+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Atrial Ejection Force in Systemic Autoimmune Diseases


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Systemic autoimmune disorders may affect several organs, including the heart. We analyzed two-dimensional and pulsed Doppler echocardiograms of patients (n = 37) with systemic lupus erythematosus (SLE, n = 24) or rheumatoid arthritis (RA, n = 13) to determine whether atrial ejection force (AEF) could represent a suitable parameter for detecting left ventricular filling abnormalities in SLE and RA. In both patient subgroups, AEF was significantly higher than in healthy controls (n = 40) matched for gender and age (14.0 ± 5.4 vs. 11.0 ± 3.5 kdyn, p < 0.01). Because conventional echocardiographic parameters of left ventricular function failed to detect such a difference, AEF might serve as an additional sensitive parameter for detecting left ventricular diastolic filling abnormalities early in the course of a systemic autoimmune disease.

          Related collections

          Most cited references 2

          • Record: found
          • Abstract: found
          • Article: not found

          Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus.

          A prospective echocardiographic study was carried out on 132 consecutive patients with systemic lupus erythematosus (SLE) derived from three European university medical centres. The prevalence of valvular lesions in patients with SLE was 22.7% compared with 2.9% in a control group of 68 healthy volunteers. 50 SLE patients had antibodies against phospholipids. The prevalence of valve vegetations (8/50 [16%]) and of mitral regurgitation (19/50 [38%]) was significantly higher among the SLE patients with antiphospholipids than among those without (1 and 10/82 [1.2% and 12%], respectively). During follow-up of the patients with valvular lesions, haemodynamically significant clinical valve disease developed in 6 but surgery was required in only 1; 9 had cerebrovascular occlusions; and 7 died, although no death was due directly to the cardiac involvement. Thus, valvular heart disease, particularly affecting the mitral valve, is common in patients with SLE, and the presence of antibodies against phospholipids is associated with a higher prevalence of valvular abnormalities in these patients.
            • Record: found
            • Abstract: found
            • Article: not found

            M-mode and two-dimensional echocardiographic abnormalities in systemic lupus erythematosus.

            A prospective clinical and echocardiographic study of 47 patients with systemic lupus erythematosus (SLE) and 46 age- and sex-matched controls showed an increased prevalence of echocardiographic abnormalities in the SLE group. Pericardial abnormalities were identified in ten patients with SLE and in no controls. Excluding mitral valve prolapse, valvular abnormalities were identified in ten patients with SLE (21%) and in three controls (7%). In the patients with SLE, abnormalities included mitral valve leaflet thickening in six, aortic valve thickening in five, and mitral annular calcification in two. The presence of valvular abnormalities correlated with duration but not with severity of SLE. The finding of systolic murmurs in 17 of 47 patients with SLE did not correlate with echocardiographic evidence of valvular disease. In six patients with SLE, valvular abnormalities detected by two-dimensional echocardiography were not seen on M-mode echocardiogram.

              Author and article information

              S. Karger AG
              April 2000
              19 April 2000
              : 92
              : 4
              : 269-274
              aDepartment of Internal Medicine, Medizinische Poliklinik, University of Würzburg, Germany; bOsaka National Hospital, Osaka, Japan
              6985 Cardiology 1999;92:269–274
              © 2000 S. Karger AG, Basel

              Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

              Page count
              Figures: 2, Tables: 1, References: 23, Pages: 6
              Noninvasive and Diagnostic Cardiology


              Comment on this article